Literature DB >> 32184960

Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Kerstin Hiesinger1, Annika Schott1, Jan S Kramer1, René Blöcher1, Finja Witt2, Sandra K Wittmann1, Dieter Steinhilber1, Denys Pogoryelov1, Jana Gerstmeier2, Oliver Werz2, Ewgenij Proschak1.   

Abstract

Multitarget anti-inflammatory drugs interfering with the arachidonic acid cascade exhibit superior efficacy. In this study, a prototype dual inhibitor of soluble epoxide hydrolase (sEH) and LTA4 hydrolase (LTA4H) with submicromolar activity toward both targets has been designed and synthesized. Preliminary structure-activity relationship studies were performed to identify optimal substitution patterns. X-ray structure analysis of a promising dual inhibitor in complex with sEH, as well as molecular docking with LTA4H provided a rationale for further optimization. Hereby, scaffold extension was successfully applied to yield potent dual sEH/LTA4H inhibitors. The spectrum of pro- and anti-inflammatory lipid mediators was evaluated in M1 and M2 macrophages, stimulated with LPS, and incubated with the most promising compound 14. The effect of 14 on the inflammatory lipid mediator profile characterizes dual sEH/LTA4H inhibitors as an interesting option for future anti-inflammatory agent investigations.
Copyright © 2019 American Chemical Society.

Entities:  

Year:  2019        PMID: 32184960      PMCID: PMC7073873          DOI: 10.1021/acsmedchemlett.9b00330

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Development of a high-throughput screen for soluble epoxide hydrolase inhibition.

Authors:  Nicola M Wolf; Christophe Morisseau; Paul D Jones; Bertold Hock; Bruce D Hammock
Journal:  Anal Biochem       Date:  2006-05-11       Impact factor: 3.365

2.  Discovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase.

Authors:  Alexey Lukin; Jan Kramer; Markus Hartmann; Lilia Weizel; Victor Hernandez-Olmos; Konstantin Falahati; Irene Burghardt; Natalia Kalinchenkova; Darya Bagnyukova; Nikolay Zhurilo; Jarkko Rautio; Markus Forsberg; Jouni Ihalainen; Seppo Auriola; Jukka Leppänen; Igor Konstantinov; Denys Pogoryelov; Ewgenij Proschak; Dmitry Dar'in; Mikhail Krasavin
Journal:  Bioorg Chem       Date:  2018-07-17       Impact factor: 5.275

3.  Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds.

Authors:  Ewgenij Proschak; Holger Stark; Daniel Merk
Journal:  J Med Chem       Date:  2018-08-03       Impact factor: 7.446

4.  Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N'-diaryl urea inhibitors of soluble epoxide hydrolase.

Authors:  Sampath-Kumar Anandan; Richard D Gless
Journal:  Bioorg Med Chem Lett       Date:  2010-03-19       Impact factor: 2.823

5.  Evaluation of structure-derived pharmacophore of soluble epoxide hydrolase inhibitors by virtual screening.

Authors:  Daniel Moser; Janosch Achenbach; Franca-Maria Klingler; Buscató Estel la; Steffen Hahn; Ewgenij Proschak
Journal:  Bioorg Med Chem Lett       Date:  2012-08-23       Impact factor: 2.823

6.  Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.

Authors:  Cheryl A Grice; Kevin L Tays; Brad M Savall; Jianmei Wei; Christopher R Butler; Frank U Axe; Scott D Bembenek; Anne M Fourie; Paul J Dunford; Katherine Lundeen; Fawn Coles; Xiaohua Xue; Jason P Riley; Kacy N Williams; Lars Karlsson; James P Edwards
Journal:  J Med Chem       Date:  2008-06-28       Impact factor: 7.446

7.  Thermodynamic properties of leukotriene A4 hydrolase inhibitors.

Authors:  Sandra K Wittmann; Lena Kalinowsky; Jan S Kramer; René Bloecher; Stefan Knapp; Dieter Steinhilber; Denys Pogoryelov; Ewgenij Proschak; Jan Heering
Journal:  Bioorg Med Chem       Date:  2016-08-26       Impact factor: 3.641

Review 8.  Development of multitarget agents possessing soluble epoxide hydrolase inhibitory activity.

Authors:  Kerstin Hiesinger; Karen M Wagner; Bruce D Hammock; Ewgenij Proschak; Sung Hee Hwang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-12-26       Impact factor: 3.072

9.  Non-urea functionality as the primary pharmacophore in soluble epoxide hydrolase inhibitors.

Authors:  Sampath-Kumar Anandan; Zung N Do; Heather K Webb; Dinesh V Patel; Richard D Gless
Journal:  Bioorg Med Chem Lett       Date:  2009-01-10       Impact factor: 2.823

10.  Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.

Authors:  Shin Numao; Franziska Hasler; Claire Laguerre; Honnappa Srinivas; Nathalie Wack; Petra Jäger; Andres Schmid; Arnaud Osmont; Patrik Röthlisberger; Jeremy Houguenade; Christian Bergsdorf; Janet Dawson; Nathalie Carte; Andreas Hofmann; Christian Markert; Liz Hardaker; Andreas Billich; Romain M Wolf; Carlos A Penno; Birgit Bollbuck; Wolfgang Miltz; Till A Röhn
Journal:  Sci Rep       Date:  2017-10-19       Impact factor: 4.379

View more
  7 in total

1.  Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Lena Hefke; Kerstin Hiesinger; W Felix Zhu; Jan S Kramer; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

2.  Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.

Authors:  Suaad A Audat; Nizar A Al-Shar'i; Buthina A Al-Oudat; Amanda Bryant-Friedrich; Mel F Bedi; Aref L Zayed; Qosay A Al-Balas
Journal:  Molecules       Date:  2020-06-22       Impact factor: 4.411

3.  Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.

Authors:  Nina V Vorobjeva; Galina F Sud'ina; Boris V Chernyak
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

4.  Systematic Assessment of Fragment Identification for Multitarget Drug Design.

Authors:  Steffen Brunst; Jan S Kramer; Whitney Kilu; Jan Heering; Julius Pollinger; Kerstin Hiesinger; Sven George; Dieter Steinhilber; Daniel Merk; Ewgenij Proschak
Journal:  ChemMedChem       Date:  2021-02-04       Impact factor: 3.466

Review 5.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

Review 6.  Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID-19.

Authors:  Manoj Manickam; Sangeetha Meenakshisundaram; Thanigaimalai Pillaiyar
Journal:  Arch Pharm (Weinheim)       Date:  2021-11-21       Impact factor: 4.613

7.  Development and in vitro Profiling of Dual FXR/LTA4H Modulators.

Authors:  Simone Schierle; Steffen Brunst; Moritz Helmstädter; Roland Ebert; Jan S Kramer; Dieter Steinhilber; Ewgenij Proschak; Daniel Merk
Journal:  ChemMedChem       Date:  2021-05-24       Impact factor: 3.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.